Radiologists Warn that Décolletage Filler May Interfere with Breast Cancer Screening

Radiologists raise concerns about décolletage fillers and breast cancer screening.

Recent FDA approval of Radiesse for the treatment of wrinkles in the décolletage area has prompted discussion among radiologists and breast health experts about the potential impact of dermal fillers on breast cancer screening.

Breast imaging specialists have warned that fillers injected into the upper chest could interfere with mammography and other breast imaging exams by appearing on images or obscuring underlying tissue, potentially complicating interpretation or delaying detection of early cancers. These concerns were raised during an FDA advisory meeting in 2025, where radiologists emphasized the importance of identifying small breast cancers as early as possible.

Despite these concerns, the FDA approved Radiesse for décollete wrinkles on April 8, 2026, making it the first regenerative biostimulator approved for both facial and body indications in the United States. As part of its approval, the FDA is requiring Merz Aesthetics to conduct a post‑approval study evaluating whether the filler interferes with breast imaging, including mammograms and ultrasound.

Merz Aesthetics has stated that there is currently no evidence that filler injected into the décolletage affects breast cancer screening. The company notes that the product may be visible on some imaging studies and advises patients to inform healthcare providers, including radiologists, of any cosmetic filler treatments in the chest area.

This discussion highlights the importance of informed consent, documentation, and patient education when offering fillers in anatomically sensitive areas. Encouraging patients to disclose prior aesthetic treatments to breast imaging providers may help support accurate screening and continuity of care.